Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Autism spectrum disorder and Alzheimer's disease : advances in research / / edited by Ghulam Ashraf and Athanasios Alexiou
| Autism spectrum disorder and Alzheimer's disease : advances in research / / edited by Ghulam Ashraf and Athanasios Alexiou |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (315 pages) |
| Disciplina | 305.9084 |
| Soggetto topico |
Autism spectrum disorders
Trastorns de l'espectre autista Malaltia d'Alzheimer Comorbiditat |
| Soggetto genere / forma | Llibres electrònics. |
| ISBN | 981-16-4558-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910544847103321 |
| Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Mechanism and Genetic Susceptibility of Neurological Disorders
| Mechanism and Genetic Susceptibility of Neurological Disorders |
| Autore | Khan Andleeb |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore Pte. Limited, , 2024 |
| Descrizione fisica | 1 online resource (425 pages) |
| Disciplina | 616.8 |
| Altri autori (Persone) |
RatherMashoque Ahmad
AshrafGhulam |
| ISBN | 981-9994-04-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Acknowledgments -- Contents -- Editors and Contributors -- About the Editors -- Contributors -- 1: Neuropathology of Neurological Disorders -- 1.1 Introduction -- 1.2 Degenerative Disorders -- 1.2.1 Alzheimer's Disease -- 1.2.1.1 Amyloid Plaques -- 1.2.1.2 Tau -- 1.2.2 Parkinson's Disease -- 1.2.2.1 Susceptibility of Neurons -- 1.2.3 Huntington's Disease -- 1.2.3.1 Basal Ganglia -- 1.2.3.2 Neuropathology of the Basal Ganglia -- Macroscopic Changes -- 1.2.3.3 Mechanisms of Neuropathology -- 1.3 Cerebrovascular Diseases -- 1.3.1 Stroke -- 1.3.2 Traumatic Brain Injury -- 1.3.2.1 Concussion -- 1.3.2.2 Contusion -- 1.4 Systemic Diseases -- 1.4.1 Multiple Sclerosis -- 1.4.1.1 Neuroinflammation: Unleashing the Disruption Within the Brain -- 1.4.1.2 Unraveling Mechanisms Behind Primary Myelin Loss -- 1.4.1.3 Unveiling the Neural Injury: Axonal Impairment in Multiple Sclerosis -- 1.5 Conclusion -- References -- 2: Head Trauma: Etiology, Pathophysiology, Clinical Manifestation, and Biomarkers -- 2.1 Introduction -- 2.2 Etiologies of Head Trauma -- 2.3 Pathophysiology of TBI -- 2.3.1 Primary Brain Injury and Secondary Injury -- 2.3.2 General Stages of Cerebral Injury After TBI -- 2.3.3 Cerebral Blood Flow -- 2.3.4 Excitotoxicity -- 2.3.5 Mitochondrial Dysfunction -- 2.3.6 ROS and Lipid Peroxidation -- 2.3.7 Edema -- 2.3.8 Neuroinflammation -- 2.3.9 Necrosis and Apoptosis -- 2.4 Clinical Manifestations of Head Trauma -- 2.4.1 Cephalohematoma -- 2.4.2 Subgaleal Hemorrhage -- 2.4.3 Concussion -- 2.4.4 Cerebral Contusion -- 2.4.5 Traumatic Axonal Injury -- 2.4.6 Skull Fractures -- 2.4.7 Intracranial Hematomas -- 2.4.7.1 Epidural Hematoma -- 2.4.7.2 Subdural Hematoma -- 2.4.7.3 Traumatic Subarachnoid Hemorrhage -- 2.5 Biomarkers -- 2.6 Future Treatments -- 2.7 Conclusion -- References.
3: Current Understanding of DNA Methylation in the Pathogenesis of Neuropathic Pain -- 3.1 Introduction -- 3.2 DNA Methylation -- 3.3 Histone Modification -- 3.4 Histone Acetylation and Deacetylation in Neuropathic Pain -- 3.5 DNA Methylation in Neuropathic Pain -- 3.6 Conclusion and Future Perspectives -- References -- 4: Decoding Dystrophin Gene Mutations: Unraveling the Mysteries of Muscular Dystrophy -- 4.1 Introduction -- 4.2 Cellular Roles of Dystrophin -- 4.3 Dystrophin-Associated Disease -- 4.4 DMD Gene Association with Neurological Disorders and Central Nervous System -- 4.5 Mutation in Dystrophin and Its Genetic Predisposition -- 4.5.1 Large (Deletion and Duplication) Mutations -- 4.5.2 Small (Point, Frameshift, Indels, Splice-Site) Mutations -- 4.6 Diagnosis of Muscular Dystrophy -- 4.7 Novel Approaches to Gene-Based Therapy: Strategies and Future Prospects -- 4.7.1 Stem Cell Therapy for DMD -- 4.7.2 CRISPR Therapeutics -- 4.7.3 Exon Skipping Therapy with Antisense Oligonucleotides -- 4.7.4 miRNAs as Serum Biomarkers -- 4.7.5 Genetic Counseling -- 4.8 Conclusion -- References -- 5: Etiology of Ataxia: A Mechanistic Insight of Autoimmune, Toxicity, and Genetic Approach -- 5.1 Introduction -- 5.2 Categorization of Ataxias -- 5.2.1 Acquired Ataxias (A-At) -- 5.2.1.1 Paraneoplastic Cerebellar Degeneration (PCD) -- 5.2.1.2 Non-paraneoplastic Cerebellar Degeneration -- Anti-GAD Ataxia -- Gluten Ataxia -- Anti-contactin-Associated Protein 2 (CASPR2) Antibody-Associated Encephalitis -- Anti-metabotropic Glutamate Receptor (mGluR1) Encephalitis -- 5.3 Inherited/Genetic Ataxia: Etiology Focused on Genetic -- 5.3.1 SCAs -- 5.3.1.1 Insight of Molecular Mechanisms -- Ataxia Associated with Polyglutamine Expansion -- SCA and Channelopathies -- Mitochondrial Dysfunction -- Autophagy -- Transcriptional Dysregulation. Genetic Modifiers -- 5.3.2 Autosomal Recessive Cerebellar Ataxias (ARCAs) -- 5.3.2.1 Underlying Pathological Mechanisms for Triggering ARCAs -- Mitochondrial Defects -- Nucleic Acid Maintenance and Its Quality Control -- Metabolisms-Associated Dysfunction -- 5.3.2.2 The Common Form of ARCAs -- Friedreich Ataxia (FA) -- Ataxia with Isolated Vitamin E Deficiency (AVED) -- Abeta Lipoproteinemia (Bassen Kornzweig Disease) (ABL) -- Cayman Ataxia (CA) -- Ataxia-Telangiectasia (AT) -- Ataxia-Telangiectasia-Like (ATL) Disorder -- Ataxia with Oculomotor Apraxia, Type 1 (AOA1) -- Ataxia with Oculomotor Apraxia, Type 2 (AOA2) -- Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) -- Infantile-Onset Spinocerebellar Ataxia (IOSCA) -- Refsum's Disease -- Cerebrotendinous Xanthomatosis (CTX) -- Marinesco-Sjogren Syndrome (MSS) -- SeSAME Syndrome (Seizures, Sensorineural Deafness, Ataxia, Mental Retardation, and Electrolyte Imbalance) -- SYNE1 Ataxia (Also Known as Autosomal Recessive (SCAR) 8, Recessive Ataxia of Beauce, Autosomal Recessive Cerebellar Ataxia, Type 1 (ARCA 1)) -- Coenzyme Q10 Deficiency Also Known as Autosomal Recessive Cerebellar Ataxia (ARCA)2 -- Posterior Column Ataxia and Retinitis Pigmentosa -- Late-Onset Tay Sachs Disease (LOTSD) -- Spinocerebellar Ataxia, Autosomal Recessive-13 (SCAR-13) -- 5.3.3 X-Linked Cerebellar Ataxia (X-CA) -- 5.4 Conclusion and Unresolved Questions -- References -- 6: miRNA Dysregulation in Schizophrenia -- 6.1 Introduction -- 6.1.1 Indication of miRNA Dysregulation in Schizophrenia -- 6.1.1.1 Study of Cortical miRNA Expression After Mortality -- 6.1.1.2 Expression of Peripheral miRNAs Linked to Schizophrenia -- 6.2 The Central Nervous System (CNS) Is Related to miRNA Biosynthesis and Activities -- 6.3 Dysregulations of MiRNAs in Schizophrenia. 6.3.1 Schizophrenia Is Associated with Modified Levels of miRNA -- 6.3.2 MiRNA Assembly Deregulation in Schizophrenia -- 6.3.3 Schizophrenia-Related SNPs Linked via miRNA -- 6.4 Mechanisms for miRNA Dysregulation in Schizophrenia -- 6.5 Alterations in miRNA Biogenesis -- 6.6 Pharmacological Impact -- 6.7 Perspective of miRNA Therapeutics -- 6.8 Conclusion -- References -- 7: Muscular Dystrophy: Underlying Cellular and Molecular Mechanisms and Various Nanotherapeutic Approaches for Muscular Dystrophy -- 7.1 Introduction -- 7.2 Types of MD -- 7.2.1 Duchenne Muscular Dystrophy (DMD) (Meryon's Disease) -- 7.2.2 Becker Muscular Dystrophy (BMD) -- 7.2.2.1 Modes of Inheritance (Including Types) -- 7.2.3 Myotonic Dystrophy (MD) -- 7.2.4 Limb-Girdle Muscular Dystrophy (LGMD) -- 7.2.4.1 Autosomal Dominant LGMD -- 7.2.4.2 Autosomal Recessive LGMD -- 7.2.5 Facioscapulohumeral Muscular Dystrophy (FSHD) -- 7.2.6 Congenital Muscular Dystrophy (CMD) -- 7.2.6.1 Fukuyama Congenital Muscular Dystrophy (FCMD) -- 7.2.6.2 Muscle Eye Brain (MEB) Disease -- 7.2.6.3 Walker-Warburg Syndrome (WWS) -- 7.2.7 Distal Muscular Dystrophy (DD) -- 7.2.8 Oculopharyngeal Muscular Dystrophy (OPMD) -- 7.2.9 Emery-Dreifuss Muscular Dystrophy (EDMD) -- 7.3 Cellular and Molecular Mechanisms Underlying Muscular Dystrophy -- 7.3.1 The Skeletal Muscle Structure -- 7.3.2 Neuro-Muscular Coordination for Muscle Contraction -- 7.3.3 Dystrophin Gene (DMD) -- 7.3.4 Dystrophin Protein and Dystrophin-Associated Protein Complex (DAPC) -- 7.3.5 Genetics and Mutations in the Human Dystrophin Gene -- 7.3.6 Consequences of Dystrophin Mutation -- 7.3.6.1 Mechanical Instability and Sarcolemma Disintegration -- 7.3.6.2 Abnormal nNOS-Mediated Cell Signaling -- 7.3.6.3 Oxidative Imbalance and Harm from Reactive Radicals -- 7.3.6.4 Chronic Inflammation. 7.3.6.5 Dysregulation of Intracellular Calcium -- 7.3.6.6 Disrupted Muscle Repair -- 7.4 Important Diagnostic Approaches for Muscular Dystrophies -- 7.5 Various Treatment Strategies for MD -- 7.5.1 Medications -- 7.5.2 Therapies -- 7.5.3 Surgery -- 7.5.4 Nano-technological Approaches for MD -- 7.5.4.1 Targeted Drug Delivery and Genes Therapy for MD Treatment -- 7.5.4.2 Nano-regenerative Approaches for MD Treatment -- 7.6 Conclusion -- References -- 8: Axonal Degeneration, Impaired Axonal Transport, and Synaptic Dysfunction in Motor Neuron Disorder -- 8.1 Historical Background -- 8.2 Introduction -- 8.3 Morphology of Neurons -- 8.3.1 Types of Neurons -- 8.4 Developmental Aspect and Regulatory Outlook in Neuronal Connections -- 8.5 Neuronal Signals and Synaptic Network Regulators -- 8.6 Mechanical Properties of Axon and Axonal Transport -- 8.7 Axonal Transport -- 8.7.1 Association of Genes in Axonal Transport -- 8.7.2 Transportation of Cargos and Cellular Moieties Across Axons -- 8.7.3 Axonal Impairment and Development of Disease -- 8.8 Axonal Transport Abnormalities and Related MND Pathogeneses -- 8.9 Conclusion -- References -- 9: Alterations in Receptor Genes in Huntington's Disease -- 9.1 Introduction -- 9.2 Pathogenesis of HD -- 9.2.1 Aggregation of Mutant Huntingtin -- 9.2.2 Transcriptional Dysregulation in HD -- 9.2.3 Epigenetic and Noncoding RNAs in HD -- 9.2.4 Role of Ubiquitin-Proteasome System and Autophagy-Lysosome System in HD -- 9.2.5 Synaptic Plasticity and Neuronal Hemostasis in HD -- 9.2.6 Cell-to-Cell Transmission of HD Aggregates -- 9.2.7 Astrocyte and Microglial Dysfunction in HD -- 9.3 Genetics of HD -- 9.3.1 Composition and Function of Wild Type of Huntingtin Gene -- 9.4 Function and Composition of Receptor Genes in HD -- 9.4.1 Role of Receptor Genes in HD -- 9.4.2 Receptor Genes Altered in HD. 9.5 Cellular Location of HD Receptor Gene Products. |
| Record Nr. | UNINA-9910847085103321 |
Khan Andleeb
|
||
| Singapore : , : Springer Singapore Pte. Limited, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||